BCBheemisetty S. Chakravarthy

Bheemisetty S. Chakravarthy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bheemisetty S. Chakravarthy has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM197-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial

    by Subhash Thuluva, Subbareddy Gunneri, Siddalingaiah Ningaiah, Vijay Yerroju, Rammohan Reddy Mogulla, Kamal Thammireddy, Shivani Desai, Venkatalakshmi Gundu, Atul Jindal, Pradeep Nanjappa, et al.

    Background/Objectives: Maternally transferred antibodies protect infants early in life, but high concentrations can reduce immune responses to primary vaccination. CRM197 is a nontoxic mutant of diphtheria toxin that retains antigenic similarity to the native protein. We therefore investigated whether anti-diphtheria antibodies present before vaccination were related to responses against pneumococcal polysaccharides conjugated to CRM197. Methods: This post hoc analysis used data from a multicenter, randomized, single-blind phase III trial in which Indian infants received BE-PCV14/PNEUBEVAX 14® at 6–8, 10–12, and 14–16 weeks of age (commonly referred to as 6–10–14 weeks). Baseline anti-diphtheria toxoid IgG concentrations measured at 6–8 weeks were assessed in relation to serotype-specific pneumococcal IgG responses 28 days after dose 3. We evaluated these associations using categorical and continuous analyses with false-discovery-rate correction for serotype-specific comparisons. Results: Baseline and post-primary results were available for 603 of 650 infants in the co-administration cohort. Post-primary pneumococcal IgG concentrations did not differ significantly across the baseline anti-diphtheria IgG categories. Individual fold rises differed nominally among baseline anti-diphtheria IgG categories for serotype 5, but the difference did not remain significant after multiplicity correction. In the adjusted continuous models, geometric mean ratios (GMRs) associated with each 2-fold increase in baseline anti-diphtheria IgG ranged from 0.978 to 1.011, with no statistically significant associations after false-discovery-rate correction. Analyses stratified by baseline pneumococcal IgG similarly showed no consistent evidence of reduced responses. Conclusions: In this cohort, pre-existing anti-diphtheria toxoid IgG measured before vaccination, which was likely maternally derived, was not associated with a consistent reduction in post-primary serotype-specific pneumococcal IgG responses to CRM197-conjugated BE-PCV14.

  • Open Access

    Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial

    by Subhash Thuluva, Subbareddy Gunneri, Siddalingaiah Ningaiah, Vijay Yerroju, Rammohan Reddy Mogulla, Kamal Thammireddy, Chirag Dhar, Shivani Desai, Piyush Paliwal, Chandrudu Loka, et al.

    Background: Pneumococcal conjugate vaccines (PCVs) have substantially reduced pneumococcal disease in children; however, serotype distribution varies geographically, and residual disease due to non-PCV13 serotypes persists. Biological E’s PNEUBEVAX 14® (BE-PCV14), a WHO-prequalified 14-valent PCV, expands coverage by including serotypes 22F and 33F. As PCVs are co-administered with routine Expanded Programme on Immunization (EPI) vaccines, post-licensure data on safety, co-administration, and lot-to-lot consistency are essential. This multicenter phase IV study evaluated BE-PCV14 in healthy PCV-naïve infants aged 6–8 weeks across 31 sites in India. Methods: A total of 2600 infants were enrolled and vaccinated at 6, 10, and 14 weeks of age; 2300 received BE-PCV14 and 300 received PCV13. All participants received concomitant DTwP-HepB-IPV-Hib and oral rotavirus vaccines per routine schedule. Safety was assessed through solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs). Immunogenicity subsets evaluated responses to co-administered vaccines and serotype-specific responses across three BE-PCV14 lots. Results: Among 2600 vaccinated infants, at least one AE occurred in 26.35% (95% CI: 24.59, 28.19) of BE-PCV14 and 24.67% (95% CI: 20.13, 29.84) of PCV13 recipients; most were mild. Injection-site pain and pyrexia were the most common events. Immune responses to co-administered vaccines were comparable between groups and met the non-inferiority criteria: lower bound of the two-sided 95% CI > −10 percentage points for seroprotection/seroconversion rate differences using the Farrington–Manning method. Lot-to-lot consistency was demonstrated, with all GMC ratios within the predefined equivalence margin (0.5–2.0). Conclusions : BE-PCV14 was well tolerated. Immune responses to co-administered routine EPI vaccines met predefined non-inferiority criteria, supporting the interpretation that BE-PCV14 did not result in clinically meaningful immune interference. Consistent immune responses across manufacturing lots further support its use in infant immunization programs.